Published in Clin Chim Acta on December 13, 1985
Free radicals and the pancreatic acinar cells: role in physiology and pathology. Philos Trans R Soc Lond B Biol Sci (2005) 0.87
Sclerosing cholangitis with hepatic microvesicular steatosis in cystic fibrosis and chronic pancreatitis. J Clin Pathol (1989) 0.86
Redox signaling in acute pancreatitis. Redox Biol (2015) 0.82
Oxygen derived free radicals in patients with chronic pancreatic and other digestive diseases. J Clin Pathol (1990) 0.80
Theophylline and antipyrine disposition in smoking and non-smoking epileptic subjects. Br J Clin Pharmacol (1987) 0.75
Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis (2000) 4.24
The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer (2012) 3.80
Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology (Oxford) (2004) 3.22
Reversal reactions in leprosy and their management. Lepr Rev (1991) 2.75
A systematic review of the literature exploring the role of primary care in genetic services. Fam Pract (1999) 2.62
Role for a phage promoter in Shiga toxin 2 expression from a pathogenic Escherichia coli strain. J Bacteriol (2001) 2.59
Diagnostic strategies used in primary care. BMJ (2009) 2.23
Regulation of the Shiga-like toxin II operon in Escherichia coli. Infect Immun (1996) 2.13
Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun (1989) 2.12
Early discharge of patients with pulmonary embolism: a two-phase observational study. Eur Respir J (2007) 2.08
Prevalence and incidence of adults consulting for shoulder conditions in UK primary care; patterns of diagnosis and referral. Rheumatology (Oxford) (2005) 2.07
Evaluation of the premier EHEC assay for detection of Shiga toxin-producing Escherichia coli. J Clin Microbiol (1997) 1.97
Cytotoxic activities of Mannich bases of chalcones and related compounds. J Med Chem (1998) 1.74
The accuracy of general practitioner records of smoking and alcohol use: comparison with patient questionnaires. J Public Health Med (2000) 1.71
Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immun (2001) 1.69
Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immun (1999) 1.66
Prevalence, antibiotic susceptibility, and diversity of Escherichia coli O157:H7 isolates from a longitudinal study of beef cattle feedlots. Appl Environ Microbiol (2001) 1.60
Prevalence of mandibular dysfunction in young adults. J Am Dent Assoc (1979) 1.54
Shortcomings of an automated assay for total antioxidant status in biological fluids. Clin Chem (1996) 1.54
Isogenic lysogens of diverse shiga toxin 2-encoding bacteriophages produce markedly different amounts of shiga toxin. Infect Immun (1999) 1.53
Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol (1997) 1.52
Laserlight cues for gait freezing in Parkinson's disease: an open-label study. Parkinsonism Relat Disord (2010) 1.51
Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun (2001) 1.49
Abnormal drug metabolism in chronic pancreatitis. Treatment with antioxidants. Gastroenterology (1990) 1.48
Human neutrophils and their products induce Shiga toxin production by enterohemorrhagic Escherichia coli. Infect Immun (2001) 1.47
Mitomycin immunoblot colony assay for detection of Shiga-like toxin-producing Escherichia coli in fecal samples: comparison with DNA probes. J Clin Microbiol (1993) 1.43
Potentiation of isoproterenol effect by ascorbic acid. Res Commun Chem Pathol Pharmacol (1976) 1.43
Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy. Clin Lab Haematol (2005) 1.39
Biliary colic on abrupt withdrawal of octreotide. Lancet (1991) 1.38
Care of a child with hypospadias: ethical issues in practice. Br J Nurs (1992) 1.38
Acute transverse myelitis and Guillain-Barré overlap syndrome with serological evidence for mumps viraemia. Acta Neurol Scand (2001) 1.38
Cervical spine movement during orotracheal intubation. Ann Emerg Med (1986) 1.34
Drug metabolite kinetics. Pharmacol Ther (1981) 1.33
Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG (2008) 1.33
Pancreatitis--a retrospective study. Gut (1976) 1.33
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol (1999) 1.33
Selective and sensitive method for PCR amplification of Escherichia coli 16S rRNA genes in soil. Appl Environ Microbiol (2000) 1.33
Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. Aliment Pharmacol Ther (1990) 1.32
Acetylcysteine to treat complications of pancreatitis. Lancet (1986) 1.32
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol (1996) 1.31
Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos (2001) 1.29
A transgenic insertion causing cryptorchidism in mice. Genesis (2001) 1.29
Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid. J Pharm Sci (1976) 1.28
Does your patient have pancreatic disease? J R Coll Physicians Lond (1982) 1.27
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother (2001) 1.25
Development of isothiocyanate-enriched broccoli, and its enhanced ability to induce phase 2 detoxification enzymes in mammalian cells. Theor Appl Genet (2002) 1.24
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus. Pharm Res (2001) 1.22
Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect Immun (1997) 1.22
Evaluation of the impact of two educational interventions on GP management of familial breast/ovarian cancer cases: a cluster randomised controlled trial. Br J Gen Pract (2001) 1.20
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. Br J Clin Pharmacol (2001) 1.19
Antioxidant therapy for recurrent pancreatitis: biochemical profiles in a placebo-controlled trial. Aliment Pharmacol Ther (1992) 1.18
Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect Immun (1999) 1.18
Effect of activated charcoal on acetaminophen absorption. Pediatrics (1976) 1.17
Observations on the BT PABA/14C-PABA tubeless test of pancreatic function. Clin Chim Acta (1983) 1.17
Azo reduction of sulphasalazine in healthy volunteers. Br J Clin Pharmacol (1982) 1.15
Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J Clin Invest (1995) 1.15
Prevention of coronary platelet aggregation with a phosphodiesterase inhibitor RX-RA 69. Thromb Res (1985) 1.14
Multivalent inhibition of AB(5) toxins. J Am Chem Soc (2001) 1.14
Supranormal 25-hydroxyvitamin D and subnormal 1,25-dihydroxyvitamin D: their role in X-linked hypophosphatemic rickets. Am J Dis Child (1980) 1.13
Pancreatic disease: a casualty of hepatic "detoxification"? Lancet (1983) 1.12
Guidelines for referral to a regional genetics service: GPs respond by referring more appropriate cases. Fam Pract (2001) 1.11
Vitamin C status in patients with acute pancreatitis. Br J Surg (1993) 1.09
Random transposon mutagenesis of Campylobacter jejuni. Infect Immun (2000) 1.08
Relationship between pancreatic exocrine function and ductal morphology in chronic pancreatitis. Gastroenterology (1982) 1.07
Dietary antioxidants and chronic pancreatitis. Hum Nutr Clin Nutr (1986) 1.06
A system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit. Infect Immun (1990) 1.05
Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol (1994) 1.03
Computed tomography in pancreatic disease. Br J Radiol (1978) 1.03
Detection by ELISA of low numbers of Shiga-like toxin-producing Escherichia coli in mixed cultures after growth in the presence of mitomycin C. J Med Microbiol (1992) 1.03
Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e. Infect Immun (1995) 1.02
The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study. Br J Cancer (2013) 1.02
Amphetamines in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry (1975) 1.02
Shiga toxin: purification, structure, and function. Rev Infect Dis (1991) 1.01
Absorption of prednisolone in patients with Crohn's disease. Gut (1983) 1.01
Expanding the role of the family history in primary care. Br J Gen Pract (1999) 1.01
Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol (1999) 1.00
Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol (1994) 0.99
Induction of drug-metabolizing enzymes in human pancreatic cancer and chronic pancreatitis. J Pathol (1993) 0.99
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol (1998) 0.98
Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis. Infect Immun (1999) 0.98
Lipid-peroxidation (free-radical-oxidation) products in bile from patients with pancreatic disease. Lancet (1983) 0.98
Heightened free radical activity in pancreatitis. Free Radic Biol Med (1990) 0.98
Hyperkalemia and cardiovascular collapse following administration of succinylcholine to the traumatized patient. Anesthesiology (1969) 0.98
Comparison of the effects of Shiga-like toxin 1 on cytokine- and butyrate-treated human umbilical and saphenous vein endothelial cells. J Infect Dis (1996) 0.97
Circulating vitamin D metabolite concentrations in childhood renal diseases. Kidney Int (1982) 0.97
Relationship between PABA and Lundh tests: lack of influence of duodenal pH in vivo. Clin Chim Acta (1983) 0.96
Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. Drug Metab Dispos (1996) 0.96
Thrombotic thrombocytopenic purpura associated with Shiga toxins. Semin Hematol (1997) 0.96
Drug metabolite concentration-time profiles: influence of route of drug administration. Br J Clin Pharmacol (1984) 0.95
Diagnosis of infections with Shiga-like toxin-producing Escherichia coli by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples. J Med Microbiol (1994) 0.95
Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines. Br J Cancer (2009) 0.94
The influence of secretin on the secretion of pepsin in response to acid stimulants in the anaesthetized cat. J Physiol (1975) 0.94
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther (2001) 0.93
Treatment of toenail onychomycosis. Prescribing terbinafine to every patient with the condition would be expensive. BMJ (1999) 0.92
Patients with haemolytic uraemic syndrome caused by Escherichia coli O157: absence of antibodies to Vero cytotoxin 1 (VT1) or VT2. J Clin Pathol (1993) 0.92
Effect of prednisone on growth and bone mineral content in childhood glomerular disease. Am J Dis Child (1978) 0.91
Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets. Pediatrics (1983) 0.91